iNtRON Biotechnology, Inc. (KOSDAQ:048530)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,740.00
-45.00 (-1.19%)
Apr 29, 2026, 3:30 PM KST
-8.33%
Market Cap 119.66B
Revenue (ttm) 5.74B
Net Income (ttm) -8.96B
Shares Out 31.61M
EPS (ttm) -283.00
PE Ratio n/a
Forward PE n/a
Dividend 100.00 (2.57%)
Ex-Dividend Date n/a
Volume 204,629
Average Volume 704,510
Open 3,785.00
Previous Close 3,785.00
Day's Range 3,665.00 - 3,840.00
52-Week Range 2,895.00 - 7,010.00
Beta 0.26
RSI 43.00
Earnings Date Mar 27, 2026

About iNtRON Biotechnology

iNtRON Biotechnology, Inc. engages in the development of novel biopharmaceutical drugs in South Korea. It develops bacteriophage and endolysin based drugs through itLysin and IMPA platform. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 73
Stock Exchange KOSDAQ
Ticker Symbol 048530
Full Company Profile

Financial Performance

In 2025, iNtRON Biotechnology's revenue was 5.74 billion, a decrease of -10.56% compared to the previous year's 6.42 billion. Losses were -8.96 billion, 245.7% more than in 2024.

Financial Statements

News

There is no news available yet.